Zeeshan Ahmad, MD
Pulmonary Disease · Salisbury, NCNPI 1235392994
Payments from drug & device makers
Across 195 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$1K
- Inspire Medical Systems, Inc.$888
- GSK$365
- Regeneron Healthcare Solutions, Inc.$274
- Sanofi$255
- Amgen$236
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,61932%
- Food & beverage$3,28566%
- Education$812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 11 | $1,139 |
| Inspire Medical Systems, Inc. | 9 | $888 |
| GSK | 23 | $365 |
| Regeneron Healthcare Solutions, Inc. | 12 | $274 |
| Sanofi | 10 | $255 |
| Amgen | 13 | $236 |
| AstraZeneca | 10 | $209 |
| Verona Pharma, Inc. | 10 | $189 |
| Philips North America LLC | 8 | $159 |
| Grifols USA, LLC | 8 | $157 |
| United Therapeutics Corporation | 23 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $94 |
| Actelion Pharmaceuticals US, Inc. | 4 | $90 |
| Baxter Healthcare | 4 | $82 |
| Insmed, Inc. | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 13 | $79 |
| Electromed, Inc. | 5 | $78 |
| Boehringer Ingelheim | 3 | $70 |
| Pfizer | 3 | $64 |
| Merck | 4 | $60 |
| Mylan Specialty L.p. | 3 | $55 |
| Viatris Specialty LLC | 2 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Resmed Corp | 1 | $35 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Masimo Corporation | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,985 in reported general payments places this provider in the 65th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $150,083 |
| OfevNintedanib Esylate | 11 | $143,053 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $65,655 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $39,968 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $26,470 |
| Spiriva RespimatTiotropium Bromide | 26 | $24,189 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 53 | $23,884 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $23,569 |
| EliquisApixaban | 16 | $15,273 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $14,144 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $4,395 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $863 |
| Montelukast Sodium | 72 | $503 |
| Gabapentin | 14 | $342 |
| Omeprazole | 17 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $70 | $190,81183 claims |
| Grifols USA, LLCProlastin C | $157 | $150,08311 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $365 | $105,623154 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $209 | $64,498131 claims |
| PfizerEliquis | $64 | $15,27316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Salisbury
- Nilesh PatelSalisbury$114K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
- Mikell JarrattGastonia$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.